Ligand Pharmaceuticals Incorporated
LGND
$213.21
-$5.77-2.64%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 215.79% | 3,186.63% | 7.38% | -280.02% | -237.65% |
| Total Depreciation and Amortization | -4.43% | -2.85% | -2.47% | -4.10% | -2.55% |
| Total Amortization of Deferred Charges | 37.47% | 23.09% | 18.70% | 29.46% | 38.20% |
| Total Other Non-Cash Items | -146.57% | -327.66% | -2,755.93% | 2,202.21% | 314.18% |
| Change in Net Operating Assets | -127.12% | -165.43% | -25.68% | 120.40% | 117.46% |
| Cash from Operations | 133.58% | -49.14% | -58.36% | 15.91% | 53.87% |
| Capital Expenditure | 75.85% | 75.18% | 24.31% | -22.51% | -59.24% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -251.72% | -160.00% | -248.58% | -16.56% | -824.77% |
| Cash from Investing | -253.02% | -162.64% | -244.97% | -2.92% | -419.09% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -419,444.44% | -453,008.00% | -471,883.33% | -7.14% | 99.96% |
| Issuance of Common Stock | -44.42% | -53.76% | -30.13% | 159.81% | 166.73% |
| Repurchase of Common Stock | -241.87% | -378.95% | -657.37% | -222.93% | -215.77% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 12,955.04% | 13,855.40% | 4,801.43% | 721.68% | 53.94% |
| Cash from Financing | 422.16% | 340.83% | 436.48% | 183.28% | 270.70% |
| Foreign Exchange rate Adjustments | 1,213.27% | 301.54% | 271.88% | -- | -- |
| Miscellaneous Cash Flow Adjustments | 200.00% | -- | -- | -- | -- |
| Net Change in Cash | 3,289.40% | 107.93% | 73.12% | 580.59% | 94.55% |